The Week Ahead: COS...
Health Care: Drugs
Merck & Co Inc (MRK: NYSE)
$47.16 -0.17 | -0.36%
05/24/13 - 04:00 PM ET
Latest Dividend:0.43
Latest Dividend Yield:3.68%
Dividend Ex-Date:03/13/13
Price Earnings Ratio:23.83
Price Earnings Comparisons:
| MRK | Sector Avg. | S&P 500 |
|---|---|---|
| 23.83 | 24.00 | 17.70 |
Price Performance History (% change):
| 3 Mo | 1 Yr | 3 Yr |
|---|---|---|
| 10.15 | 26.75 | 47.72 |
| GROWTH | 12 Mo | 3 Yr | CAGR |
|---|---|---|---|
| Revenue | -1.60 | 0.72 | 0.20 |
| Net Income | 0.00 | 0.00 | |
| EPS | -1.00 | -0.64 | -0.29 |
Earnings for MRK:
| EBITDA | 16.86B |
| REVENUE | 47.27B |
Average Earnings Estimates
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $0.83 | $0.92 | $3.49 | $3.78 |
| Number of Analysts | 7 | 6 | 10 | 10 |
| High Estimate | $0.87 | $0.95 | $3.56 | $4.00 |
| Low Estimate | $0.80 | $0.88 | $3.44 | $3.64 |
| Prior Year | $1.05 | $0.95 | $3.82 | $3.49 |
| Growth Rate (Year over Year) | -20.95% | -3.68% | -8.56% | 8.30% |
Portfolios with MRK
- Portfolio NameUser Type
- User2013
- ContributorStocks Rising On Unusual Vo...
- UserJeeper Portfolio 1
- UserCapt Jer
- Userlennyvb Portfolio 1
- ContributorDogs of the Dow 2013
- ContributorTechnical Setups for the We...
- ContributorHigh Volume Technicals for ...
- UserCovered Calls
- Contributor9 Dow Dividend Stocks With ...
Latest MRK Headlines from TheStreet
- Cramer's 'Mad Money' Recap: Haves and Have-Nots 04.17.13 | 08:04 pm
- Cramer Talks Abbott & Glaxo
04.17.13 | 03:04 pm - March Into Merck, Aflac and Nordstrom Shares 04.17.13 | 02:04 pm
- 'Mad Money' Uncovered: Big Pharma on a Down Day in the Market 04.15.13 | 01:04 pm
- Mad Money Uncovered: Merck and the Pharma Laggards 04.15.13 | 12:04 pm
- Merck & Co Inc Stock Buy Recommendation Reiterated (MRK) 04.15.13 | 10:04 am
- Cramer's 'Mad Money' Recap: The Bulls Are In Charge 04.10.13 | 08:04 pm
- Merck & Co Inc (MRK): Health Care's Featured Stock Of The Day 04.10.13 | 05:04 pm
- Cramer's Top Stock Picks: MKC MRK PCLN EXPE TJX 04.10.13 | 06:04 am
- Cramer's 'Mad Money' Recap: As China Goes... 04.09.13 | 08:04 pm
Press Releases for MRK
- Pharmaceutical Companies, Investor Coalition Develop Industry Standard-Setting Principles For Recoupment Policies Covering Major Compliance Failures - PR Newswire 04.04.13 | 08:04 am
- Merck Announces FDA Acceptance Of Biologics License Application For Investigational Grass Pollen Allergy Immunotherapy Tablet - Business Wire 03.27.13 | 08:03 am
- Merck And Luminex Corporation Enter Agreement To Develop Companion Diagnostic To Support Investigational BACE Inhibitor Clinical Development Program For Alzheimer’s Disease - Business Wire 03.13.13 | 08:03 am
- Results From HPS2-THRIVE Study Of TREDAPTIVE™ (extended-release Niacin/laropiprant) Presented At American College Of Cardiology Scientific Sessions - Business Wire 03.09.13 | 12:03 pm
- Roger M. Perlmutter (Photo: Business Wire) - Business Wire 03.07.13 | 07:03 am
- Merck To Present At The 33rd Annual Cowen Health Care Conference - Business Wire 03.05.13 | 08:03 am
- Merck Announces Second-Quarter 2013 Dividend - Business Wire 02.26.13 | 02:02 pm
- Merck To Present At The Citi 2013 Global Healthcare Conference - Business Wire 02.26.13 | 08:02 am
- Merck To Present New Data Analyses Of Its Investigational Ragweed Pollen And Grass Pollen Allergy Immunotherapy Tablets - Business Wire 02.22.13 | 08:02 am
- Merck And Samsung Bioepis Enter Biosimilars Development And Commercialization Agreement - Business Wire 02.20.13 | 07:02 am
Partner Headlines for MRK
- Companies slide $181B through tax loopholes - MSN Money 04.19.13 | 10:04 am
- Revive leadership in pharma R&D - Financial Times 04.17.13 | 08:04 pm
- Market Close Report: NASDAQ Composite index closes at 3,297.25 up 59.39 points - NASDAQ 04.10.13 | 08:04 pm
- Market Close Report: NASDAQ Composite index closes at 3,218.60 down -36.26 points - NASDAQ 04.03.13 | 08:04 pm
- 10 Sharp Healthcare Dogs Diagnose 7.4% To 62.1% Gains In March - Seeking Alpha 04.01.13 | 09:04 am
- New foot-and-mouth vaccine developed - Financial Times 03.27.13 | 11:03 pm
- 'Pay For Delay' Case Could Change Generic Drug Rules - Investor's Business Daily 03.26.13 | 04:03 pm
- Common Sense Says Time For Quality, Dividends And Premiums - Seeking Alpha 03.23.13 | 06:03 am
- Top 9 March Healthcare Dogs Mark 3.4% To 28.7% Gains - Seeking Alpha 03.23.13 | 04:03 am
- Looking For Bargains And Safety - Seeking Alpha 03.17.13 | 09:03 am
